분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2010-10-17 17:57:12 , Hit : 3006
 Roche hepatitis C drug appears safe in combination

HONG KONG | Thu Oct 14, 2010 7:01pm EDT

HONG KONG Oct 15 (Reuters) - Two experimental drugs -- one of them belonging to Switzerland's Roche (ROG.VX) -- appear to be safe and well-tolerated by hepatitis C patients when used in combination, researchers reported on Friday.

The search for new treatments for hepatitis C has gained urgency because the present cocktail -- interferon and ribavirin -- has serious side effects and a growing number of people do not respond to interferon anymore.

In a paper published in The Lancet, researchers in Australia, New Zealand and the United States said patients who were given the two experimental drugs -- danoprevir and Roche's RG7128 -- appeared to tolerate the combination well.

A total of 88 patients in Australia and New Zealand participated in the 13-day phase 1 trial, of whom 14 were given placebo, or drugs with no therapeutic effect.

The rest were divided into seven groups and given both drugs in different dosages.

Patients who were given the highest doses -- 1,000 milligrams of RG7128 and 900 mg of danoprevir twice daily -- showed huge reductions in viral loads by day 13.

"Our study was to combine two different drugs with two different mechanisms of action; they target different parts of the virus," said professor Edward Gane of Auckland City Hospital and Auckland District Health Board in New Zealand.

"We wanted to see if we can prevent emergence of resistance and suppress the virus and this is certainly what was shown. There were no cases of resistance in this study."

Viral loads for several of the patients given the highest doses fell to below detection levels, they said in the paper.

Gane said neither drug should be used in isolation because of the speed at which this virus mutates.

"When you use these drugs by themselves, even though they are very well tolerated and have very little side effect, the virus rapidly mutates and becomes resistant to them," he said.

The patients complained of headache, lethargy, rash, gastrointestinal disorders and nausea but they were mild to moderate, the researchers said.

Worldwide, more than 170 million people are infected with the hepatitis C, a disease that can result in liver cirrhosis, or hardening, and finally liver cancer. (Reporting by Tan Ee Lyn; Editing by Sugita Katyal)








787   Gene Editing Treats Blood Disease  이성욱 2011/07/16 3067
786   A pathogenic picornavirus acquires an envelope by hijacking cellular membranes  이성욱 2013/04/23 3062
785   The Sugar Lnc  이성욱 2012/05/10 3039
784   A targeted cancer therapy? - small conditional RNA  이성욱 2010/09/08 3024
  Roche hepatitis C drug appears safe in combination  이성욱 2010/10/17 3006
782   More support for transcription trickPosted by Jef Akst  이성욱 2010/05/01 3006
781   면역 시스템을 가지는 바이러스  이성욱 2013/03/01 2997
780   배아 발달 동안 돌연변이와 성인에서 암 발병 관련성  이성욱 2012/06/18 2989
779   유전자 특허 불인정 판결의 후폭풍: 멘붕에 빠진 미 BT 업계  이성욱 2013/06/20 2986
778   Hepatitis C Virus Infection Linked to Fat Enzyme in Liver Cells  이성욱 2010/10/15 2983
777   Sugars recruited in fight against persistent infections  이성욱 2011/05/17 2970
776   Gene Therapy Appears to Help Patient With Anemia  이성욱 2010/09/17 2967
775   Viruses in the gut protect from infection  이성욱 2013/05/22 2950
774   Molecular scalpel hope for Duchenne muscular dystrophyBy James Gallagher  이성욱 2011/07/28 2949
773   Pluripotency not required !!!  이성욱 2010/01/28 2943
772   Autistic Mice Act a Lot Like Human Patients: Geneticists Develop Promising Mouse Model for Testing New Autism Therapies  이성욱 2011/10/06 2937
771   Why brain tumors hard to treat  이성욱 2010/11/23 2928
770   C형간염 진단 유전자검사 개발  이성욱 2013/03/07 2927
769   줄기세포 이식으로 HIV 감염 완치: 세계 3번째, 4번째의 HIV 완치 환자 등장  이성욱 2013/07/05 2917
768   More support for RNAi in clinic  이성욱 2010/03/23 2912

[이전 10개] [1]..[21][22][23][24] 25 [26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN